Peter Blume-Jensen, Acrivon Therapeutics CEO (via YouTube)
October 19, 2022 09:14 AM EDTUpdated October 20, 02:27 PM
Financing
Deals

Can a lit­tle start­up equipped with an Eli Lil­ly castoff make it big with an on­col­o­gy IPO? In 2022?

John Carroll

Editor & Founder

The ex­ec­u­tive crew and back­ers at the lit­tle start­up Acrivon clear­ly aren’t averse to risk. They hand­ed over a mod­est $5 mil­lion in cash to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times